Page last updated: 2024-09-03

gefitinib and Carcinoma, Squamous Cell

gefitinib has been researched along with Carcinoma, Squamous Cell in 263 studies

*Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) [MeSH]

Research

Studies (263)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	125 (47.53)	29.6817
2010's	126 (47.91)	24.3611
2020's	12 (4.56)	2.80

Authors

Authors	Studies
Ashton, SE; Barker, AJ; Barlow, JJ; Curry, BJ; Gibson, KH; Godfrey, AA; Grundy, W; Healy, MP; Henthorn, L; Richards, L; Scarlett, L; Woodburn, JR	1
Guo, C; Lan, M; Li, S; Li, Y; Sun, X; Tang, Y; Zhan, D; Zhao, H	1
Lei, S; Li, B; Li, S; Wang, J; Wang, Q; Yu, C; Zhang, Z	1
Chen, BS; Lin, YC	1
Feng, YF; Lei, YY; Liu, W; Luo, HH; Yang, HS; Zheng, SY	1
Kim, MS; Yang, SH	1
Cheng, SJ; Deng, YT; Ko, HH; Kuo, MY; Lee, HC; Lu, YJ; Peng, HH	1
Bai, J; Cai, S; Chen, H; Gao, C; Han, R; He, Y; Jiang, L; Li, L; Ren, B; Sun, J; Tian, K; Wang, H; Wang, Y; Wu, G; Xiao, HL; Xu, Z; Yang, Z; Zhang, XJ; Zhao, Y; Zhou, Q; Zhou, X	1
Ding, Z; Liu, H; Ou, C; Zhou, L	1
Guan, R; Hu, D; Jiang, W; Li, K; Li, Y; Liao, D; Liu, L; Mansfield, AS; Wang, J; Xia, C; Xiao, L; Xiong, Y; Yang, H; Yang, N; Zeng, L; Zhang, Y; Zhou, C	1
Bleilevens, A; Denecke, B; Denzinger, S; Ecke, T; Eltze, E; Eyll, M; Gaisa, NT; Geelvink, M; Gereitzig, M; Grimm, T; Herrmann, E; Horst, D; Knuechel, R; Maurer, A; Maurer, J; Rose, M; Rüchel, N; Toma, M; Vögeli, TA; Waldmann, T; Wenz, M; Wirtz, J	1
Bermejo, JO; Bernat-Peguera, A; Bosio, M; Capella-Gutierrez, S; da Silva-Diz, V; González-Suárez, E; Lorenzo-Sanz, L; Mesia, R; Muñoz, P; Navarro-Ventura, J; Palomero, L; Penin, RM; Pérez Sidelnikova, D; Piulats, JM; Taberna, M; Vilariño, N; Villanueva, A; Viñals, F; Viñals, JM	1
Chen, X; Chen, Z; Hu, Y; Li, C; Li, K; Li, Y; Liu, P; Liu, Q; Song, F; Sui, X; Wang, J; Wang, X; Yang, F; Zhang, Y; Zou, B	1
Bu, T; Xu, A; Yan, H	1
Favre, L; Helissey, C; Lamboley, JL; Mamou, E; Nguyen, AT	1
Kannan, S; Sinto, MS; Thomas, S	1
Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD	1
Jameson, MJ; Khalil, A	1
Bertrand, D; Chia, S; Chong, FT; DasGupta, R; Gopalakrishna Iyer, N; Hentze, H; Hui Choo, S; Hwang, JSG; Koh, JLY; Kwang, XL; Leong, HS; Lezhava, A; Lim, KH; Low, JL; Periyasamy, G; Sharma, A; Skanthakumar, T; Su, Y; Tan, DSW; Tan, HK; Tan, IBH; Tan, P; Thangavelu, MT; Toh, SY; Zhang, X	1
Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X	1
Feng, L; Ferrarotto, R; Ginsberg, L; Glisson, B; Kies, M; Kim, ES; Lippman, S; William, WN	1
Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L	1
Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N	1
D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M	1
Furukawa, R; Matsumoto, Y; Ohara, S; Taniguchi, Y; Usui, K	1
He, R; Liu, Y; Luo, H; Luo, J; Pi, G; Quan, J; Su, X; Wang, G; Xiao, H; Ye, Y; Zhang, Q; Zhao, L	1
Chai, Y; Wu, Y; Yao, Y; Zhu, Z	1
Hase, T; Hasegawa, Y; Matsui, A; Morise, M; Omote, N; Sato, M; Shimoyama, Y; Suzuki, K; Tanaka, I	1
Amoroso, V; Baggi, A; Berruti, A; Intagliata, S; Nonnis, D; Pozzari, M; Roca, E; Tovazzi, V; Vermi, W	1
Cui, L; Liu, Y; Niu, M; Qian, W; Qu, X; Song, J; Tian, J; Zhang, L; Zhao, J; Zhao, M; Zheng, B; Zhou, M	1
Agarwal, V; Nayar, RC; Rao, V; Subash, A	1
Gaffney, DC; Simpson, F; Soyer, HP	1
Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K	1
Bontognali, S; Brutsche, MH; Buess, M; Fischer, C; Pless, M; Rochlitz, C	1
Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A	1
Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K	1
Azuma, J; Fujio, Y; Furukawa, M; Imamura, F; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Mori, M; Namba, Y; Nonen, S; Otani, Y; Tachibana, I; Takimoto, T; Tsuruta, N; Uchida, J; Yokota, S	1
Bellevicine, C; Carlomagno, C; De Luca, C; de Rosa, N; De Stefano, A; Iaccarino, A; Illiano, A; Malapelle, U; Micheli, P; Pepe, F; Piantedosi, FV; Rocco, D; Russo, S; Salatiello, M; Troncone, G; Vitiello, F	1
Kato, H; Oizumi, H; Sadahiro, M; Watarai, H	1
Chen, CY; Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Tseng, SC; Wo, TY	1
Cohen, PR; Jalalat, SZ	1
Hishima, T; Hosomi, Y; Kato, K; Nagamata, M; Okamura, T; Okuma, Y; Sekihara, K; Yamada, Y	1
Koyama, N; Uchida, Y	1
Nakagawa, K; Okamoto, I; Takeda, M	1
Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M	1
Hirata, M; Kagawa, S; Kanai, Y; Kawai, K; Naka, S; Nishii, R; Ohmomo, Y; Yoshimoto, M	1
Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C	1
Adejumo, O; Allak, A; Hubbard, MA; Jameson, MJ; Khalil, AA; Maxwell, AK; Mendez, RE; Schoeff, SS; VanKoevering, KK	1
Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Karaseva, NA; Kulikova, YE; Lozhkina, AM; Mitiushkina, NV; Orlov, SV; Tiurin, VI; Togo, AV; Volodina, LN	1
Chiara, MD; de Santa-María, IS; Merlo, A; Secades, P; Suarez, C	1
Ford, HE	1
Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J	1
Benaich, N; Huang, Y; Kwok, HF; Murphy, G; Tape, C	1
Jiao, SC; Peng, L; Song, ZG	1
Cai, Z; Yang, X; Zhang, L; Zhao, B	1
Chou, YH; Hsieh, MS; Hua, SF; Jhuang, JY	1
Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL	1
Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP	1
Cui, G; Cui, M; Guo, H; Li, W; Li, Y; Liang, Y; Zhao, S	1
Bill, A; Bonenfant, D; Duvvuri, U; Gaither, LA; Gutierrez, A; Kemp, C; Kulkarni, S; Voshol, H	1
Gao, K; Li, XY; Liang, Y; Wu, N; Zhang, LF; Zhou, LN	1
Chasapi, V; Soura, E; Stratigos, AJ	1
Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A	1
Uhara, H	1
Doddapaneni, R; Godugu, C; Mercer, R; Patel, AR; Singh, M; Singh, R	1
Gu, J; Hu, J; Mao, W; Sun, W; Sun, X; Wu, W; Xu, Y; Yu, X; Zhang, G; Zheng, Y	1
Cherpelis, B; Rudnick, EW; Thareja, S	1
Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV	1
Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM	1
Chavez, J; De La Chapa, JJ; Dybdal-Hargreaves, NF; Gonzales, CB; Horning, AM; Kirma, NB; Parra, J; Saikumar, P; Singha, PK	1
Fan, Z; Li, X; Lu, H; Lu, Y; Qiu, S	1
Cataisson, C; Krymskaya, L; Mascia, F; McKinnon, KM; Schloemann, DT; Wolcott, KM; Yuspa, SH	1
Kataoka, K; Okamura, Y; Osaka, E; Shimizu, T; Tokuhashi, Y; Yoshida, Y	1
Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G	1
Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L	1
Chen, H; Dong, D; Dong, L; Fu, M; Hong, R; Liu, X; Lu, N; Ma, L; Ou, Y; Song, Y; Xiao, W; Xue, L; Zhan, Q; Zhang, W; Zhao, Z	1
Arteaga, CL; Engelman, JA; Faber, AC; Guix, M; Olivares, MG; Qu, S; Rinehart, C; Seidel, B; Song, Y; Wang, SE; Yee, D	1
Greene, MI; Wang, Q	1
Adamo, V; Caponigro, F; Franchin, G; Mari, E; Milano, A; Morrica, B; Pepe, S; Romano, C; Solla, R	1
Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Sano, D; Taguchi, T; Toth, G; Tsukuda, M	1
Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM	1
Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H	1
Eguchi, K; Ishizaka, A; Kawada, I; Kawamura, M; Kobayashi, K; Nakachi, I; Naoki, K; Soejima, K; Watanabe, H; Yasuda, H	1
Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H	1
Abidoye, O; Salgia, R; Sattler, M	1
Black, J; Iyer, R; Javle, M; LeVea, C; Nava, H; Nwogu, C; Pande, A; Wilding, G; Yang, G	1
Endo, T; Funayama, Y; Furukawa, K; Hashimoto, T; Hayashibara, K; Ichimura, H; Inagaki, M; Ishikawa, H; Ishikawa, S; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nawa, T; Satoh, H; Shinohara, Y; Sumi, M	1
Homes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, N; Rogers, AM; Yonesaka, K; Zejnullahu, K; Zhao, F	1
Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C	1
Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL	1
Barbachano, Y; Box, C; Chambers, P; Eccles, SA; Harrington, KJ; Nutting, CM; Rhŷs-Evans, P; Rogers, SJ; Workman, P	1
Hirai, Y; Kawago, M; Kiyoi, M; Naito, K; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T	1
Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR	1
Armour, A; Cohen, EE; Garin, AM; Ghiorghiu, S; Hargreaves, L; Hirsch, FR; Khorprasert, C; Licitra, L; Rischin, D; Soulieres, D; Speake, G; Stewart, JS; Swaisland, A; Van Herpen, CM; Varella-Garcia, M; Vodvarka, P; Vokes, EE	1
Allen, CT; Calvo, KR; Chen, Z; Dabir, B; Friedman, J; Morris, JC; Mundinger, GS; Pernas, FG; Saigal, K; Van Waes, C; Winters, ME; Xu, X; Yan, B	1
Li, L; Li, XQ; Liu, H; Liu, XJ; Zhen, YS	1
Cohen, EE; Cooper, JB	1
Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC	1
He, C; Liu, M; Ouyang, M; Xu, J; Zhang, J; Zhong, N; Zhou, C	1
Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R	1
Hata, R; Imagawa-Ishiguro, Y; Ito, S; Kato, Y; Komori, R; Kubota, E; Maehata, Y; Ozawa, S; Ozono, S; Shiiki, N; Taguchi, T; Tsukinoki, K; Tsukuda, M	1
Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C	1
Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ	1
Adelstein, DJ; Ives, DI; Mason, DP; Murthy, SC; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Videtic, GM	1
Duan, HQ; Han, Y; Liu, XQ; Xu, JM; Zhang, JS; Zhang, Y	1
Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q	1
Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M	1
Chen, YM; Chou, KT; Fan, WC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Wu, CH	1
Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Sung, JH; Yun, T	1
Anderton, J; Barlaam, B; Beck, S; Callis, R; Davenport, S; Grosios, K; Hickinson, DM; Klinowska, T; Marshall, G; Mills, E; Ogilvie, D; Smith, P; Speake, G; Trigwell, C; Vincent, J; Wilkinson, RW	1
Bozec, A; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Milano, G	1
Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G	1
Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S	1
Aikou, T; Akiba, S; Baba, M; Castillo, A; Eizuru, Y; Higashi, M; Itoh, T; Khan, N; Koriyama, C; Matsumoto, H; Natsugoe, S; Shuyama, KY; Yanagi, M	1
Gao, ZQ; Gu, AQ; Han, BH; Shi, CL; Wang, HM; Xiong, LW	1
Choi, YJ; Kim, CH; Kim, HR; Kim, HT; Kim, YM; Koh, JS; Kook, EH; Lee, JC; Rho, JK	1
Brückl, WM; Ficker, JH; Wiest, GH	1
Chang, SH; Hsu, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ	1
Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X	1
Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Nishiyama, A; Tomii, K; Yoshioka, H	1
Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME	1
Arcila, ME; Azzoli, CG; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA	1
Becker, A; Chiappori, A; Haura, EB; Sommers, E; Song, L	1
Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ	1
Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM	1
Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N	1
Ferreira, CG; Herchenhorn, D	1
Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC	1
Fan, Z; Li, X; Liang, K; Lu, Y; Luwor, RB	1
Argyle, DJ; Bergkvist, GT; Muirhead, R; Pang, LY; Yool, DA	1
Dyckhoff, G; Gottschling, S; Herpel, E; Kuhnt, T; Pelz, T; Penzel, R; Schnabel, PA; Thomas, M	1
Hopper, C; Jerjes, W; Mahil, J; Sudhoff, H; Upile, T	1
Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H	1
Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M	1
Bruzzese, F; Budillon, A; Caraglia, M; Carbone, C; Di Gennaro, E; Leone, A; Piro, G; Rocco, M	1
Chen, YY; Kiura, K; Noujima, D; Ochi, N; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D	1
Chen, C; D'Cruz, AK; Fijuth, J; Gregoire, V; Hamoir, M; Julka, PK; Kane, M; Kawecki, A; Korzeniowski, S; Kumar, RR; Machiels, JP; Prasad, S; Raben, D; Radosevic-Jelic, L; Sellers, MV; Tchakov, I; Wang, HM	1
Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N	1
Liebmann, C; Weisheit, S	1
Adelstein, DJ; Ives, DI; Michal, SA; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG	1
Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF	1
Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG	1
Agulnik, M	1
Chambers, MS; El-Naggar, AK; Feng, L; Glisson, BS; Lewis, CM; Lustig, RA; Rosenthal, DI; Tang, X; Wan, F; Weber, RS; Wistuba, II	1
Han, R; He, JK; Qin, ZH; Reid, PF; Wang, JH; Wu, JC; Xie, Y	1
Argyle, DJ; Bergkvist, GT; Cervantes-Arias, A; Muirhead, R; Pang, LY; Yool, DA	1
Abhold, EL; Altuna, X; Blair, KJ; Brumund, KT; Haas, M; Kiang, A; Kuo, SZ; Lopez, JP; Ongkeko, WM; Patel, A; Rahimy, E; Wang-Rodriguez, J; Weisman, RA; Yu, MA	1
Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N	1
Fujita, S; Hata, A; Imai, Y; Kaji, R; Katakami, N; Kida, Y; Tanaka, K	1
Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE	1
Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG	1
Buechner, SA; Erne, P; Joshi, MB; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ	1
Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D	1
Chang, J; Cho, BC; Hong, S; Jung, M; Kang, YA; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Rha, SY	1
An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML	1
Amagaya, S; Chang, CM; Chang, PY; Chen, MY; Jao, HY; Kuo, SC; Lee, CY; Lu, CC; Tu, MG; Yang, JS	1
Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N	1
Johansson, AC; La Fleur, L; Roberg, K	1
Bossi, P; Cortelazzi, B; Licitra, L; Locati, LD; Maurichi, A; Perrone, F; Pilotti, S; Resteghini, C	1
Beckler, AD; Carlson, HT; Francom, CR; Jameson, MJ; Khalil, AA; Mendez, RE; Stuart, MM; Taniguchi, LE; Thomas, CY; VanKoevering, KK	1
Cohen, EE; Grushko, T; Liu, J; Liu, W; Olopade, OI; Pierce, C; Seiwert, TY; Shen, C; Wei, TF; Young, NR	1
Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP	1
Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H	1
Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM	1
Buechner, SA; Erne, P; Iezzi, G; Kyriakakis, E; Pfaff, D; Philippova, M; Resink, TJ; Schoenenberger, AW; Spagnoli, GC	1
Armstrong, EA; Harari, PM; Huang, SM; Li, J	1
Cullinane, C; Hagekyriakou, J; McArthur, GA; Solomon, B; Stacker, SA; Trivett, MK	1
Abbruzzese, A; Avallone, A; Barbarino, M; Bruzzese, F; Budillon, A; Caponigro, F; Caraglia, M; Comella, P; De Lorenzo, S; Di Gennaro, E; Pepe, S	1
Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; Hong, WK; Kumar, R; Mandal, M; Yang, Z	1
Almqvist, Y; Carlsson, J; Sundberg, AL; Tolmachev, V	1
Cohen, EE; Huo, D; Recant, W; Rosen, F; Stadler, WM; Stenson, K; Vokes, EE	1
Arteaga, CL; Barbieri, CE; Matheny, KE; Pietenpol, JA; Sniezek, JC	1
Almqvist, Y; Blomquist, E; Carlsson, J; Gedda, L; Jensen, HJ; Orlova, A; Sundberg, AL; Tolmachev, V	1
Hamakawa, H; Kayahara, H; Kiyota, A; Mihara, M; Nakashiro, K; Shintani, S; Sumida, T	1
Hamakawa, H; Li, C; Mihara, M; Nakashiro, K; Shintani, S; Terakado, N; Yano, J	2
Hamakawa, H; Li, C; Mihara, M; Nakashiro, K; Shintani, S	1
Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA	1
Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z	1
Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J	1
Ochs, JS	1
Fujii, T; Hirata, A; Kinoshita, H; Kometani, T; Kuwano, M; Miyagawa, M; Ono, M; Ueda, S	1
Guan, ZZ; Jiang, WQ; Lin, TY; Wang, SS; Zhang, L	1
Argiris, A; Mittal, N	1
Campagnoli, E; Cavina, R; Grimaldi, GC; Latteri, F; Morenghi, E; Parra, HS; Roncalli, M; Santoro, A; Zucali, PA	1
Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S	1
Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT	1
Bamias, A; Efstathiou, E; Stratigos, A; Zorzou, MP	1
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X	1
Chang, GC; Chen, KC; Hsu, JY; Kuo, BI; Lin, CP; Yang, TY; Yin, MC	1
Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P	1
Cole, IE; Gallagher, RM; Kalish, LH; Kwong, RA; Musgrove, EA; Sutherland, RL	1
Von Pawel, J	1
Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ	1
Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC	1
Matsuo, K; Tanimoto, M; Uchida, A	1
Burdak-Rothkamm, S; Feldmann, K; Ludwig, D; Nguyen, TP; Rübe, C; Rübe, CE; Wiegel, T	1
Lanzi, C; Supino, R; Zanchi, C; Zuco, V; Zunino, F	1
Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO	1
Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ	1
Endo, K; Fujii, Y; Fukai, I; Iuchi, K; Kawaguchi, T; Kawahara, M; Konishi, A; Matsumura, A; Okumura, M; Sasaki, H; Shimizu, T; Takada, M; Takeuchi, H; Tanaka, H; Yano, M	1
Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T	1
Aoe, M; Doihara, H; Hara, F; Ohta, T; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Toyooka, S; Tsukuda, K; Yoshitomi, S	1
Fujiwara, T; Kagawa, S; Kawashima, T; Nisizaki, M; Tanaka, N; Tango, Y; Teraishi, F; Umeoka, T; Watanabe, T	1
Baltaci, M; Derler, AM; Fritsch, P; Höpfl, R; Sögner, P; Tzankov, A; Weber, F	1
Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K	1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X	1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X	1
Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA	1
Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T	1
Bell, DW; Brannigan, BW; Clark, JR; Cohen, EE; Dahiya, S; Haber, DA; Harris, PL; Haserlat, SM; Lingen, MW; Martin, LE; Muir, B; Okimoto, RA; Rocco, JW; Sgroi, DC; Vokes, EE	1
Belinchón, I; Pascual, JC; Sivera, F; Yuste, A	1
Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE	1
Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Nyati, MK; Scheurer, AM	1
Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N	1
Aguilera, J; Altuna, X; Chen, JS; Chu, TS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J; Weisman, RA	1
Khuri, FR; Saba, NF; Shin, DM	1
Al-Dayel, F; Al-Jommah, N; Al-Kuraya, K; Amr, S; Bavi, P; Ezzat, A; Guido, S; Sheikh, S; Simon, R; Siraj, AK	1
Fish-Steagall, A; Searcy, P; Sipples, R	1
Cohen, EE	1
Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH	1
Aldanondo, I; Fernández-Guarino, M; Garrido, P; González-García, C; Jaén, P; Marquet, A; Pérez-García, B	1
Elenius, K; Erjala, K; Grenman, R; Junttila, TT; Kulmala, J; Mali, P; Pulkkinen, J; Savisalo, M; Sundvall, M; Zhang, N	1
Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY	1
Fukutome, M; Maebayashi, K; Mitsuhashi, N; Nasu, S; Seki, K	1
Chen, YM; Chiu, CH; Lin, WC; Liou, JL; Perng, RP; Tsai, CM	1
Erjala, K; Grénman, R; Kulmala, J; Raitanen, M	1
Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N	1
Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T	1
Eckardt, A; Morgan, MA; Reuter, CW	1
Jeon, NK; Kim, J; Lee, EJ; Whang, JH	1
Aoe, M; Date, H; Kiura, K; Kosaka, T; Mitsudomi, T; Ogino, A; Ouchida, M; Shigematsu, H; Soh, J; Takata, M; Toyooka, S; Uchida, A	1
Fujimura, M; Ichikawa, Y; Ishiura, Y; Kasahara, K; Kashii, T; Kimura, H; Kita, T; Kobayashi, M; Kunitoh, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shiarasaki, H; Shibata, K; Sone, T; Tamura, T; Waseda, Y; Watanabe, K; Yoshimoto, A	1
Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY	1
Fischer, JR; Geiger, D; Haffner, UJ; Lahm, H	1
Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X	1
Foley, J; Gilmore, JL; Gonterman, RM; Koltz, PF; Konger, RL; Laughner, R; Lewis, DA; Lorch, G; Nadella, KS; Rosol, TJ; Toribio, RE	1
Bunn, PA; Chan, D; Coldren, CD; Frederick, BA; Helfrich, BA; Raben, D; Zheng, D	1
Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y	1
Azzoli, CG; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Pizzo, B; Riely, GJ; Rizvi, NA	1
Kubota, K	1
Gyergyay, F	1
Tsukuda, M	1
Duan, HQ; Han, Y; Liu, XQ; Song, ST; Xu, JM; Zhang, JS; Zhang, Y	1
Abe, D; Amano, Y; Fujii, A; Kitano, Y; Nakamura, H; Ohya, J; Suzuki, T	1
Daly, RJ; Lehrbach, GM; Musgrove, EA; Sutherland, RL; Timpson, P; Wilson, AS	1
Elenius, K; Erjala, K; Grénman, R; Kulmala, J; Sundvall, M; Zhang, N	1
Baron, A; Campana, J; Chen, C; Dancey, J; Eckhardt, SG; Harrison, L; Hu, K; Kane, M; Quon, H; Raben, A; Raben, D; Said, S; Song, J	1
Carrasco, AT; Chaigneau, L; Extra, JM; Fabbro, M; Floquet, A; Gladieff, L; Goncalves, A; Lhommé, C; Viens, P	1
Imagawa-Ishiguro, Y; Kato, Y; Sano, D; Taguchi, T; Tsukuda, M	1
Au, GK; Chua, DT; Nicholls, J; Sham, JS; Wei, WI; Wong, MP	1
Al Moustafa, AE	1
Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC	1
Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M	1
Advani, S; Aggarwal, S; Babu, G; Bhattacharyya, GS; Chacko, RT; Chang, AY; Digumarti, R; Doval, DC; Hargreaves, L; Jagannathan, R; Nag, S; Parikh, P; Ranade, A; Thatcher, N	1
Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P	1
Accardi, R; Azzariti, A; Conti, D; LaCalamita, R; Paradiso, A; Pilato, B; Porcelli, L; Sebastian, S; Simone, GM; Tommasi, S; Tommasino, M	1
Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A	1
Albanell, J; Anido, J; Baselga, J; Codony-Servat, J; Del Campo, JM; Giralt, J; Mendelsohn, J; Nicholson, RI; Raspall, G; Rojo, F; Roselló, J; Sauleda, S	1
Chan, E; Cherrington, JM; Christensen, JG; Cui, J; Liu, L; Mendel, DB; Schreck, RE; Sun, L; Wang, X; Wei, J; Yang, C	1
Dubreuil, A; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G	1
Bakanauskas, VJ; Bernhard, EJ; Cerniglia, GJ; Feldman, MD; Goldsmith, JD; Gupta, AK; Machtay, M; McKenna, WG; Mick, R; Muschel, RJ; Rosenthal, DI; Weber, CN; Weber, RS	1
Hirata, A; Kometani, T; Kuwano, M; Kuwano, T; Naito, S; Ogawa, S; Ono, M	1

Reviews

25 review(s) available for gefitinib and Carcinoma, Squamous Cell

Article	Year
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case. Lung cancer (Amsterdam, Netherlands), 2019, Volume: 127 Topics: Acrylamides; Adenocarcinoma; Adult; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Prognosis; Protein Kinase Inhibitors	2019
The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target. The Australasian journal of dermatology, 2014, Volume: 55, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Panitumumab; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms	2014
Pharmacologic treatment options for advanced epithelial skin cancer. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:10 Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome	2015
[Molecular target therapies for skin cancers]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; CTLA-4 Antigen; Enzyme Inhibitors; Gefitinib; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Quinazolines; Skin Neoplasms	2015
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. International journal of dermatology, 2016, Volume: 55, Issue:3 Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden	2016
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. The Cochrane database of systematic reviews, 2015, Dec-01, Issue:12 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids	2015
EGFR inhibition as a therapy for head and neck squamous cell carcinoma. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2008
EGFR-targeted therapeutics: focus on SCCHN and NSCLC. TheScientificWorldJournal, 2008, Sep-21, Volume: 8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines	2008
Mechanisms of resistance to EGFR inhibitors in head and neck cancer. Head & neck, 2009, Volume: 31, Issue:8 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Signal Transduction; Treatment Outcome	2009
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?]. Pneumologie (Stuttgart, Germany), 2010, Volume: 64, Issue:12 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2010
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head & neck, 2010, Volume: 32, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines	2010
KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-20, Volume: 29, Issue:21 Topics: Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Time Factors; Tomography, X-Ray Computed; Tonsillar Neoplasms; Treatment Outcome	2011
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4 Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2012
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2012, Volume: 269, Issue:10 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles	2012
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2012, Volume: 18, Issue:6 Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab	2012
[Targeting of epidermal growth factor receptor and applications in ORL cancer]. Bulletin du cancer, 2003, Volume: 90 Spec No Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines	2003
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3 Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents	2004
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bulletin du cancer, 2004, May-01, Volume: 91, Issue:5 Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines	2004
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park, N.Y.), 2006, Volume: 20, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines	2006
Clinical experience with anti-EGFR therapy. Seminars in oncology nursing, 2006, Volume: 22, Issue:1 Suppl 1 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome	2006
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome	2006
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. British journal of cancer, 2007, Feb-12, Volume: 96, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2007
[What is drug-epidemiology?]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Jun-10, Volume: 96, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Quinazolines	2007
[Head and neck: molecular-targeted therapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines	2007
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings, 2008, Volume: 83, Issue:5 Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome	2008

Trials

43 trial(s) available for gefitinib and Carcinoma, Squamous Cell

Article	Year
Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23 Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Mutation; Prognosis; Survival Rate	2019
Therapeutic effect of gefitinib on patients with advanced EGFR-mutation NSCLC. Pakistan journal of pharmaceutical sciences, 2021, Volume: 34, Issue:1(Special) Topics: Adenocarcinoma of Lung; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Endoglin; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Keratin-19; Lung Neoplasms; Male; Matrix Metalloproteinase 9; Middle Aged; Pemetrexed; Th1-Th2 Balance; Vascular Endothelial Growth Factor A	2021
Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. Journal of the American Academy of Dermatology, 2017, Volume: 77, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Skin Neoplasms	2017
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Apr-10, Volume: 31, Issue:11 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome	2013
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib. Onkologie, 2013, Volume: 36, Issue:4 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome	2013
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Xenograft Model Antitumor Assays	2013
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment	2014
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma. Cancer biology & therapy, 2015, Volume: 16, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome	2015
Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study. Oncotarget, 2015, Nov-10, Volume: 6, Issue:35 Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2015
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. Anti-cancer drugs, 2008, Volume: 19, Issue:7 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Quinazolines; Radiotherapy Dosage	2008
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:10 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Health Surveys; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome	2008
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. American journal of clinical oncology, 2008, Volume: 31, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Treatment Outcome	2008
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. American journal of clinical oncology, 2008, Volume: 31, Issue:6 Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Gefitinib; Head and Neck Neoplasms; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Prognosis; Quinazolines; Radiation Injuries; Radiotherapy; Stomatitis	2008
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer, 2009, May-15, Volume: 115, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome	2009
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-10, Volume: 27, Issue:11 Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome	2009
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral oncology, 2009, Volume: 45, Issue:10 Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome	2009
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis	2010
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, Emission-Computed; Treatment Outcome; Ultrasonography	2010
[Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate	2010
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome	2010
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Cohort Studies; ErbB Receptors; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome	2010
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate	2012
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011, Volume: 100, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Double-Blind Method; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Squamous Cell Carcinoma of Head and Neck	2011
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck. Head & neck, 2012, Volume: 34, Issue:11 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult	2012
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Skin Neoplasms; Survival Analysis; Treatment Outcome	2012
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral oncology, 2012, Volume: 48, Issue:9 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Gefitinib; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin	2012
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, May-15, Volume: 21, Issue:10 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Illinois; Immunohistochemistry; Intubation, Gastrointestinal; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Treatment Outcome	2003
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC cancer, 2004, Aug-19, Volume: 4 Topics: Acne Vulgaris; Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Remission Induction; Stomatitis; Treatment Outcome	2004
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides	2005
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial. Clinical lung cancer, 2005, Volume: 7, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Psychomotor Performance; Quality of Life; Quinazolines; Treatment Outcome	2005
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Salvage Therapy; Survival Rate; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A	2005
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate	2006
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2006, Volume: 1, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines	2006
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type]. Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction	2007
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome	2007
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer, 2007, Aug-01, Volume: 110, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Survival Rate; United States	2007
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines	2007
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic oncology, 2008, Volume: 108, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Uterine Cervical Neoplasms	2008
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma. Head & neck, 2008, Volume: 30, Issue:7 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome	2008
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-20, Volume: 26, Issue:15 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids	2008
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate	2008
Clinical experience with gefitinib in Indian patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; India; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Rate	2008
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Chromones; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; ras Proteins; Signal Transduction	2002

Other Studies

195 other study(ies) available for gefitinib and Carcinoma, Squamous Cell

Article	Year
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorganic & medicinal chemistry letters, 2001, Jul-23, Volume: 11, Issue:14 Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; KB Cells; Quinazolines; Sensitivity and Specificity; Tumor Cells, Cultured	2001
Synthesis and biological evaluation of quinazoline and quinoline bearing 2,2,6,6-tetramethylpiperidine-N-oxyl as potential epidermal growth factor receptor(EGFR) tyrosine kinase inhibitors and EPR bio-probe agents. European journal of medicinal chemistry, 2012, Volume: 49 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Electron Spin Resonance Spectroscopy; ErbB Receptors; Humans; Models, Molecular; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Spin Labels	2012
miR-145-5p Modulates Gefitinib Resistance by Targeting NRAS and MEST in Non-Small Cell Lung Cancer. Annals of clinical and laboratory science, 2021, Volume: 51, Issue:5 Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Lung Neoplasms; Membrane Proteins; Mice, Nude; MicroRNAs; Prognosis; Proteins; Xenograft Model Antitumor Assays	2021
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications. International journal of molecular sciences, 2022, Sep-08, Volume: 23, Issue:18 Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Metformin; Mouth Neoplasms; NF-kappa B; Squamous Cell Carcinoma of Head and Neck; Systems Biology	2022
Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration. BMC bioinformatics, 2022, Sep-30, Volume: 23, Issue:1 Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gefitinib; Humans; Oxidative Stress; Prognosis; Sorafenib; Tumor Microenvironment; Tumor Suppressor Protein p53	2022
Role of ABCA2 and its single nucleotide polymorphisms (4873T>A and 4879G>C) in the regulation of multi-drug resistance in oral squamous carcinoma cells. Biochemical and biophysical research communications, 2023, 07-23, Volume: 666 Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; HEK293 Cells; Humans; Mouth Neoplasms; Polymorphism, Single Nucleotide	2023
Lysyl oxidase-like 2 promotes stemness and enhances antitumor effects of gefitinib in head and neck cancer via IFIT1 and IFIT3. Cancer science, 2023, Volume: 114, Issue:10 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mouth Neoplasms; Protein-Lysine 6-Oxidase; RNA-Binding Proteins; Squamous Cell Carcinoma of Head and Neck	2023
Chloroquine promotes gefitinib‑induced apoptosis by inhibiting protective autophagy in cutaneous squamous cell carcinoma. Molecular medicine reports, 2019, Volume: 20, Issue:6 Topics: Antimalarials; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Chloroquine; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Protein Kinase Inhibitors; Skin Neoplasms	2019
Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. Lung cancer (Amsterdam, Netherlands), 2020, Volume: 141 Topics: Adenocarcinoma of Lung; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Young Adult	2020
EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer. Oncogene, 2020, Volume: 39, Issue:44 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Line, Tumor; Cohort Studies; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Small Interfering; Signal Transduction; Urinary Bladder; Urinary Bladder Neoplasms	2020
FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 03-01, Volume: 27, Issue:5 Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplasms, Glandular and Epithelial; Protein Kinase Inhibitors; Receptor, Fibroblast Growth Factor, Type 1; Skin Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2021
Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nature communications, 2021, 05-10, Volume: 12, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Organoids; Pharmaceutical Preparations; Xenograft Model Antitumor Assays	2021
What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature. Anti-cancer drugs, 2022, 01-01, Volume: 33, Issue:1 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors	2022
Combinatorial treatment with Gefitinib and Bay11-7085 sensitizes primary Gefitinib-resistant OSCC cells by influencing the EGFR- NFκB signaling axis. Medical oncology (Northwood, London, England), 2021, Aug-06, Volume: 38, Issue:9 Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mouth Neoplasms; NF-kappa B; Protein Kinase Inhibitors; RNA-Seq; Tumor Cells, Cultured	2021
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas. Anticancer research, 2017, Volume: 37, Issue:6 Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines	2017
The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro. Drugs in R&D, 2017, Volume: 17, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mouth Neoplasms; Quinazolines	2017
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time. Nature communications, 2017, 09-05, Volume: 8, Issue:1 Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred NOD; Mouth Neoplasms; Phenotype; Phosphoproteins; Precision Medicine; Quinazolines; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins	2017
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nature medicine, 2017, Volume: 23, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2017
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells. BMC research notes, 2017, Nov-02, Volume: 10, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine	2017
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells. Oncology reports, 2018, Volume: 39, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays	2018
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer. Oncology research, 2018, Aug-23, Volume: 26, Issue:7 Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate	2018
The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations. International journal of clinical oncology, 2018, Volume: 23, Issue:3 Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome	2018
FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib. Oncology reports, 2018, Volume: 39, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Humans; Inhibitory Concentration 50; Male; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1	2018
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report. Medicine, 2018, Volume: 97, Issue:18 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma	2018
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib. Internal medicine (Tokyo, Japan), 2018, Dec-01, Volume: 57, Issue:23 Topics: Adenocarcinoma of Lung; Afatinib; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases	2018
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma. European radiology, 2019, Volume: 29, Issue:5 Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multidetector Computed Tomography; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies	2019
Is EGFR really a therapeutic target in head and neck cancers? Journal of surgical oncology, 2019, Volume: 119, Issue:6 Topics: Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Radiotherapy, Adjuvant	2019
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate	2013
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. Clinical lung cancer, 2013, Volume: 14, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Follow-Up Studies; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines	2013
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients. Cancer cytopathology, 2013, Volume: 121, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2013
[Long survival case of resected lung cancer after chemotherapy with gefitinib]. Kyobu geka. The Japanese journal of thoracic surgery, 2013, Volume: 66, Issue:9 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Male; Mediastinum; Pneumonectomy; Quinazolines; Time Factors	2013
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 82, Issue:3 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Metformin; Mutation; MutS Homolog 2 Protein; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transgenes	2013
Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation. Dermatology online journal, 2013, Oct-16, Volume: 19, Issue:10 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Parotid Neoplasms; Quinazolines; Vitiligo	2013
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Anticancer research, 2013, Volume: 33, Issue:11 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate	2013
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations. Anticancer research, 2013, Volume: 33, Issue:11 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate	2013
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate	2014
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. International journal of cancer, 2014, Oct-01, Volume: 135, Issue:7 Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured	2014
Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression. Biological & pharmaceutical bulletin, 2014, Volume: 37, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, Emission-Computed, Single-Photon	2014
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations. The oncologist, 2014, Volume: 19, Issue:4 Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium	2014
Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014, Volume: 151, Issue:1 Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Feasibility Studies; Gefitinib; Head and Neck Neoplasms; Heterografts; Immunoassay; In Vitro Techniques; Mice; Nanotechnology; Quinazolines	2014
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:4 Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Large Cell; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Molecular Sequence Data; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines	2014
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth fact Head & neck, 2015, Volume: 37, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; In Vitro Techniques; Membrane Proteins; Polymerase Chain Reaction; Predictive Value of Tests; Proto-Oncogene Proteins; Quinazolines; Sensitivity and Specificity; Signal Transduction; Vascular Endothelial Growth Factor A	2015
Gefitinib for oesophageal cancer: a cog in need of a wheel? The Lancet. Oncology, 2014, Volume: 15, Issue:8 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Quinazolines	2014
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation. International journal of biological sciences, 2014, Volume: 10, Issue:7 Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Antibodies; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Membrane Proteins; Phosphorylation; Quinazolines; Signal Transduction	2014
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations. Scientific reports, 2014, Aug-18, Volume: 4 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies	2014
Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015, Volume: 36, Issue:4 Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays	2015
Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment. The Annals of thoracic surgery, 2015, Volume: 99, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines	2015
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult	2014
Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:4 Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Endocytosis; ErbB Receptors; Esophageal Neoplasms; Galectin 3; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2015
ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer. Oncotarget, 2015, Apr-20, Volume: 6, Issue:11 Topics: Anoctamin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chloride Channels; ErbB Receptors; Fusion Regulatory Protein 1, Heavy Chain; Gefitinib; Head and Neck Neoplasms; HEK293 Cells; Humans; Multiprotein Complexes; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2015
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response. World journal of surgical oncology, 2015, Mar-15, Volume: 13 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; ROC Curve; Tissue Distribution; Tomography, X-Ray Computed; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2015
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro. Anticancer research, 2015, Volume: 35, Issue:7 Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin	2015
Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma. Pharmaceutical research, 2016, Volume: 33, Issue:1 Topics: Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Caco-2 Cells; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Excipients; Gefitinib; Humans; Mice, Nude; Proteomics; Quinazolines; Rats; Rats, Sprague-Dawley; Skin Neoplasms; Solubility; Survival Analysis; Xenograft Model Antitumor Assays	2016
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, 08-01, Volume: 22, Issue:15 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck	2016
Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma. Oral oncology, 2016, Volume: 59 Topics: Anaplastic Lymphoma Kinase; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Mice, Nude; Mouth Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays	2016
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer letters, 2016, 10-10, Volume: 381, Issue:1 Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection	2016
Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas. International journal of cancer, 2016, 12-01, Volume: 139, Issue:11 Topics: Animals; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Immunocompetence; Keratinocytes; Mice; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms	2016
Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case. Thoracic cancer, 2016, Volume: 7, Issue:6 Topics: Arm; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Soft Tissue Neoplasms; Treatment Outcome	2016
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma. Lung cancer (Amsterdam, Netherlands), 2017, Volume: 103 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2017
Gefitinib enhances radiotherapeutic effects of Nuclear medicine and biology, 2017, Volume: 48 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Protein Transport; Quinazolines; Radiation Tolerance; Radiochemistry; Tissue Distribution	2017
Piccolo mediates EGFR signaling and acts as a prognostic biomarker in esophageal squamous cell carcinoma. Oncogene, 2017, 07-06, Volume: 36, Issue:27 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cytoskeletal Proteins; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Neoplasm Transplantation; Neuropeptides; Prognosis; Proportional Hazards Models; Protein Stability; Protein Transport; Quinazolines; Signal Transduction	2017
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. The Journal of clinical investigation, 2008, Volume: 118, Issue:7 Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1; Xenograft Model Antitumor Assays	2008
Mechanisms of resistance to ErbB-targeted cancer therapeutics. The Journal of clinical investigation, 2008, Volume: 118, Issue:7 Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Mice; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays	2008
Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab. Oncology reports, 2008, Volume: 20, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured	2008
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 64, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome	2009
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Quinazolines	2008
A population-based study of gefitinib in patients with non-small cell lung cancer. Medical oncology (Northwood, London, England), 2009, Volume: 26, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Demography; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking	2009
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21 Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; EGF Family of Proteins; Gefitinib; Genes, erbB-1; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines	2008
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Mar-01, Volume: 15, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured	2009
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. The Journal of pathology, 2009, Volume: 218, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Genes, erbB-2; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Linear Models; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Quinazolines	2009
Histoculture drug response assay for gefitinib in non-small-cell lung cancer. General thoracic and cardiovascular surgery, 2009, Volume: 57, Issue:3 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Smoking; Tissue Culture Techniques	2009
Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Apr-01, Volume: 15, Issue:7 Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; NF-kappa B; Phosphorylation; Protein Array Analysis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction	2009
Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells. Anti-cancer drugs, 2009, Volume: 20, Issue:1 Topics: Aminoglycosides; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enediynes; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction	2009
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathology oncology research : POR, 2009, Volume: 15, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis	2009
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer. International journal of cancer, 2009, Nov-15, Volume: 125, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate	2009
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma. Cancer science, 2009, Volume: 100, Issue:11 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemokines, CXC; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mutation; Quinazolines; RNA, Messenger	2009
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:1 Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome	2010
[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib]. Chinese journal of cancer, 2010, Volume: 29, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Remission Induction; Survival Rate	2010
Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines. Anticancer research, 2009, Volume: 29, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Autophagy; Carcinoma, Squamous Cell; Caspase 3; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Gefitinib; HL-60 Cells; Humans; Methotrexate; Mitoxantrone; Mouth; Mouth Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Sodium Fluoride; Tumor Cells, Cultured	2009
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010, Volume: 19, Issue:2 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization	2010
Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult	2010
First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2010
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-15, Volume: 16, Issue:4 Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Mice; Mice, Nude; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays	2010
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib. Oral oncology, 2010, Volume: 46, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Transplantation, Heterologous	2010
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome	2010
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer. Acta medica Okayama, 2010, Volume: 64, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids	2010
Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. Oncology reports, 2010, Volume: 23, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Prevalence; Quinazolines; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53	2010
Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib. Oncology research, 2010, Volume: 18, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured	2010
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer. Clinical lung cancer, 2010, Jul-01, Volume: 11, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome	2010
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:10 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Sequence Deletion	2010
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Distribution; Tyrosine	2010
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan	2011
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured	2011
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer science, 2011, Volume: 102, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome	2011
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Apr-01, Volume: 29, Issue:10 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiotherapy, Adjuvant; Treatment Outcome	2011
Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer letters, 2011, Jul-01, Volume: 306, Issue:1 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Genes, ras; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Phosphorylation; Quinazolines; ras Proteins; Vulvar Neoplasms	2011
Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors. Cancer biology & therapy, 2011, Jun-01, Volume: 11, Issue:11 Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cats; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Conserved Sequence; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance; RNA Interference; Signal Transduction	2011
The use of optical technology to monitor the antiangiogenic effects of gefitinib treatment for advanced head and neck squamous cell carcinoma: a brief report. Lasers in medical science, 2012, Volume: 27, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Endoscopy; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Optics and Photonics; Quinazolines	2012
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Jul-01, Volume: 17, Issue:13 Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays	2011
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer. Respirology (Carlton, Vic.), 2011, Volume: 16, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines	2011
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of cellular physiology, 2011, Volume: 226, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Ubiquitination; Vorinostat	2011
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung. Lung cancer (Amsterdam, Netherlands), 2011, Volume: 73, Issue:3 Topics: Brain Neoplasms; Breath Tests; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Exhalation; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Sequence Deletion; Smoking	2011
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clinical lung cancer, 2012, Volume: 13, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome	2012
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors. Cellular signalling, 2012, Volume: 24, Issue:2 Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Dimerization; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Immunoprecipitation; Lapatinib; Plasmids; Protein Conformation; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection	2012
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly. Head & neck, 2012, Volume: 34, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enteral Nutrition; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Neutropenia; Quinazolines; Radiotherapy Dosage; Registries; Retrospective Studies	2012
Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Real-Time Polymerase Chain Reaction	2011
Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cells. Oncology reports, 2012, Volume: 27, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Cycle; Cell Line, Tumor; Crotoxin; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Xenograft Model Antitumor Assays	2012
Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition. Veterinary journal (London, England : 1997), 2012, Volume: 193, Issue:1 Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycoproteins; Head and Neck Neoplasms; Humans; Neoplastic Stem Cells; Peptides; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2012
EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PloS one, 2012, Volume: 7, Issue:2 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplasm Invasiveness; Neoplastic Stem Cells; Quinazolines; Signal Transduction	2012
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation. Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Smoking; Taxoids; Tomography, X-Ray Computed	2012
[Mutation testing for non-small-cell lung cancer]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2012, Apr-30, Volume: 132, Issue:8 Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines	2012
T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility. The Journal of investigative dermatology, 2012, Volume: 132, Issue:9 Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lapatinib; Membrane Microdomains; Quinazolines; rho GTP-Binding Proteins; Signal Transduction; Skin Neoplasms	2012
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma. International journal of cancer, 2013, Mar-01, Volume: 132, Issue:5 Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2013
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. Yonsei medical journal, 2012, Volume: 53, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Keratin-19; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Factors	2012
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 2012, Volume: 35, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome	2012
Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2 Oncology reports, 2012, Volume: 28, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mouth Neoplasms; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Wound Healing	2012
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells. PloS one, 2012, Volume: 7, Issue:9 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Drug Synergism; Fibroblasts; Gefitinib; Gene Deletion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lovastatin; Metformin; Mice; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction	2012
A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PloS one, 2012, Volume: 7, Issue:9 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Cell Shape; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Flow Cytometry; Gamma Rays; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Organ Specificity; Quinazolines	2012
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:5 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lymphatic Metastasis; Male; Quinazolines; Sirolimus; Skin Neoplasms; Skin Ulcer; TOR Serine-Threonine Kinases	2012
Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2013, Volume: 42, Issue:4 Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cyclin D; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor I; Mouth Neoplasms; Oncogene Protein v-akt; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; S Phase; Subcellular Fractions	2013
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Molecular oncology, 2013, Volume: 7, Issue:3 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mutation; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck	2013
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:1 Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion	2013
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC cancer, 2013, Jan-18, Volume: 13 Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; DNA, Viral; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Proportional Hazards Models; Quinazolines; Retrospective Studies	2013
T-cadherin loss promotes experimental metastasis of squamous cell carcinoma. European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8 Topics: Animals; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Endothelial Cells; ErbB Receptors; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Skin Neoplasms; Transendothelial and Transepithelial Migration; Transplantation, Heterologous	2013
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer research, 2002, Aug-01, Volume: 62, Issue:15 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Endothelium, Vascular; ErbB Receptors; Female; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2002
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. International journal of radiation oncology, biology, physics, 2003, Mar-01, Volume: 55, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells. Journal of cellular physiology, 2003, Volume: 195, Issue:1 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Macromolecular Substances; Oligonucleotides, Antisense; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins	2003
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Molecular cancer therapeutics, 2003, Volume: 2, Issue:4 Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Cells, Cultured; Cytoskeleton; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Keratinocytes; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms	2003
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:5 Topics: Astatine; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioma; Humans; Metabolic Clearance Rate; Protein-Tyrosine Kinases; Quinazolines; Radioisotopes; Radiopharmaceuticals	2003
Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells. The Laryngoscope, 2003, Volume: 113, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mouth Neoplasms; Phosphoproteins; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Signal Transduction; Trans-Activators; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins	2003
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:10 Topics: Antineoplastic Agents; Astatine; Astrocytoma; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Epidermal Growth Factor; Gefitinib; Humans; Quinazolines; Radiopharmaceuticals; Treatment Outcome	2003
Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor. American journal of clinical oncology, 2003, Volume: 26, Issue:5 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance	2003
Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. International journal of cancer, 2003, Dec-20, Volume: 107, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Flow Cytometry; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay	2003
Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer letters, 2003, Nov-25, Volume: 201, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Inhibitors; ErbB Receptors; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Focal Adhesions; Gefitinib; Green Fluorescent Proteins; Integrins; Luminescent Proteins; Lymph Nodes; Lymphatic Metastasis; Mice; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tongue Neoplasms; Tumor Cells, Cultured	2003
Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines. Oral oncology, 2004, Volume: 40, Issue:1 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; S Phase; Tumor Suppressor Proteins; Up-Regulation	2004
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis	2004
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin	2004
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Molecular cancer therapeutics, 2004, Volume: 3, Issue:4 Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Ubiquitin-Protein Ligases	2004
[Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor ZD1839 on nasopharyngeal carcinoma cells]. Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:5 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Fluorouracil; G1 Phase; Gefitinib; Humans; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines	2004
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2004, Volume: 43, Issue:3 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate	2004
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer. British journal of cancer, 2004, Jul-19, Volume: 91, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Survival Rate	2004
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer research, 2004, Aug-01, Volume: 64, Issue:15 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured	2004
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor. Acta dermato-venereologica, 2004, Volume: 84, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Recurrence; Severity of Illness Index	2004
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins	2004
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Investigational new drugs, 2005, Volume: 23, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme Inhibitors; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate	2005
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer, 2004, Nov-23, Volume: 4 Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms	2004
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22 Topics: Antineoplastic Agents; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Prognosis; Protein Kinase Inhibitors; Quinazolines; S Phase; Time Factors	2004
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer biology & therapy, 2004, Volume: 3, Issue:12 Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured	2004
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan	2004
APL during gefitinib treatment for non-small-cell lung cancer. The New England journal of medicine, 2005, Feb-24, Volume: 352, Issue:8 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines	2005
Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa). Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2005, Volume: 181, Issue:3 Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance	2005
Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839. Cancer research, 2005, Mar-15, Volume: 65, Issue:6 Topics: Adamantane; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 8; Caspases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cinnamates; DNA Damage; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Signal Transduction; Vulvar Neoplasms	2005
Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome	2005
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6 Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured	2005
EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-15, Volume: 11, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Polymerase Chain Reaction; Quinazolines	2005
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids	2005
Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer letters, 2005, Aug-08, Volume: 226, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured	2005
ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS letters, 2005, Aug-01, Volume: 579, Issue:19 Topics: Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Esophageal Neoplasms; G1 Phase; Gefitinib; Humans; Membrane Glycoproteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Up-Regulation	2005
Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma. The British journal of dermatology, 2005, Volume: 153, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Facial Neoplasms; Gefitinib; Humans; Male; Quinazolines; Skin Neoplasms	2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides	2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2005
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:7 Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome	2005
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Nov-15, Volume: 11, Issue:22 Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome	2005
Severe cutaneous toxicity following treatment with gefitinib (ZD1839). The British journal of dermatology, 2005, Volume: 153, Issue:6 Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Eruptions; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines	2005
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer research, 2006, Jan-15, Volume: 66, Issue:2 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Drug Administration Schedule; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Quinazolines; Tumor Cells, Cultured	2006
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer research, 2006, Mar-15, Volume: 66, Issue:6 Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A	2006
EGFR regulates the side population in head and neck squamous cell carcinoma. The Laryngoscope, 2006, Volume: 116, Issue:3 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Vitro Techniques; Neoplasm Proteins; Quinazolines	2006
High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population. Human pathology, 2006, Volume: 37, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Saudi Arabia; Tissue Array Analysis	2006
Synchronous multiple primary lung cancers with different response to gefitinib. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 53, Issue:2 Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Quinazolines; Tomography, X-Ray Computed	2006
[Gefitinib-induced perforating dermatosis]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Skin Ulcer	2006
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Structure-Activity Relationship; Time Factors	2006
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients. Lung cancer (Amsterdam, Netherlands), 2006, Volume: 54, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Characteristics; Smoking; Survival Analysis	2006
Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin"). International journal of radiation oncology, biology, physics, 2006, Oct-01, Volume: 66, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; G2 Phase; Gefitinib; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase Kinase 2; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Trastuzumab	2006
Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines. Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:3 Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Vinblastine; Vinorelbine	2007
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate	2007
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. British journal of cancer, 2006, Nov-20, Volume: 95, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome	2006
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism. Annals of the New York Academy of Sciences, 2007, Volume: 1095 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Matrix Metalloproteinases; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Tongue Neoplasms; Tumor Suppressor Protein p53	2007
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Transfection; Tumor Cells, Cultured	2007
[Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status]. Pneumologie (Stuttgart, Germany), 2007, Volume: 61, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Deletion	2007
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids	2007
Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice. British journal of cancer, 2007, Jul-16, Volume: 97, Issue:2 Topics: Amphiregulin; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; EGF Family of Proteins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hypercalcemia; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Parathyroid Hormone-Related Protein; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Signal Transduction; Xenograft Model Antitumor Assays	2007
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Molecular cancer therapeutics, 2007, Volume: 6, Issue:6 Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Head and Neck Neoplasms; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Quinazolines	2007
[Role of targeted therapy in the treatment of squamous cell head and neck cancer]. Magyar onkologia, 2007, Volume: 51, Issue:2 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant	2007
[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:4 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Prognosis; Quinazolines; Sequence Deletion	2007
Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor. Cancer science, 2007, Volume: 98, Issue:12 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recombinant Proteins	2007
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib. Cancer research, 2007, Oct-01, Volume: 67, Issue:19 Topics: Anoikis; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Growth Processes; Chromosomes, Human, Pair 11; Cortactin; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction	2007
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2007, Volume: 85, Issue:1 Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Receptor, ErbB-3; Vinblastine; Vinorelbine	2007
Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncology reports, 2008, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Molecular Sequence Data; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2008
Human cervical carcinomas and EGF-R tyrosine kinase inhibitors. Gynecologic oncology, 2008, Volume: 109, Issue:2 Topics: Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Uterine Cervical Neoplasms	2008
Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. International journal of molecular medicine, 2008, Volume: 21, Issue:6 Topics: Acid Anhydride Hydrolases; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; DNA-Binding Proteins; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Membrane Proteins; Mutation; Neoplasm Proteins; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins	2008
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer research, 2001, Aug-01, Volume: 61, Issue:15 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured	2001
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer research, 2001, Sep-01, Volume: 61, Issue:17 Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Keratinocytes; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction; Skin; Transforming Growth Factor beta	2001
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:12 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Piperazines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Tumor Cells, Cultured	2001
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. British journal of cancer, 2002, Mar-04, Volume: 86, Issue:5 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gefitinib; Genes, p53; Head and Neck Neoplasms; Humans; Quinazolines; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured	2002
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer research, 2002, May-01, Volume: 62, Issue:9 Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Movement; Cells, Cultured; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-8; Lymphokines; Male; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Physiologic; Quinazolines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vulvar Neoplasms	2002